The ADAPT trial involves 70 refractory glaucoma patients, focusing on a 12-month primary effectiveness endpoint to evaluate the Calibreye TGT Surgical System. The Calibreye system is the first ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results